Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Mounjaro"


25 mentions found


The winners NVDA YTD mountain Nvidia (NVDA) year-to-date performance Nvidia came in No. META YTD mountain Meta Platforms (META) year-to-date performance Meta Platforms climbed 37.2% in the first quarter, coming in at second place within the portfolio. The laggards AAPL YTD mountain Apple (AAPL) year-to-date performance Apple suffered the most first-quarter losses in the portfolio, slumping 10.9% during the period. FL YTD mountain Foot Locker (FL) year-to-date performance Shares of Foot Locker declined 8.5% in the first quarter, making the sneaker retailer the second-worst-performing stock in the portfolio. PANW YTD mountain Palo Alto Networks (PANW) year-to-date performance Palo Alto Networks stock fell 3.7% during the first quarter, rounding out No.
Persons: Dow, chipmaker, It's, Instagram, Meta's, Jim Cramer, Walt Disney, Nelson Peltz, Jim, Peltz's Trian, Eli Lilly, LLY, Eli Lilly's, Apple, Locker's, Locker, Jim Cramer's, Jensen Huang, Ann Wang Organizations: Dow Jones Industrial, Nasdaq, Nvidia, Facebook, Wall, DIS, Walt Disney, Peltz, Peltz's Trian Partners, Disney, U.S, Department of, Apple, Evercore ISI, Citigroup, Nike, Starbucks, Palo Alto Networks, Palo, Jim Cramer's Charitable, CNBC Locations: China, Seattle, U.S, Palo, Taipei, Taiwan
A new GLP-1 drug, pemvidutide, helped patients lose fat while guarding muscle, like exercise does. That's impressive when you compare it to existing GLP-1 drugs like Ozempic and Wegovy (semaglutide), or Mounjaro and Zepbound (tirzepatide). This is why doctors recommend patients on weight loss drugs do some strength training in tandem with their medication. Pemvidutide, like tirzepatide is a two-part drug that combines a GLP-1 drug with another drug in a single shot. "There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss," Scott Harris, Altimmune's chief medical officer, said in a release.
Persons: Drugmakers Eli Lilly, , Drugmaker Altimmune, Altimmune, Scott Harris, Eli Lilly, FierceBiotech, Versanis Organizations: Novo Nordisk, Service Locations: Altimmune, GLP
CNN —Medicare shelled out $5.7 billion on Ozempic and other similar diabetes drugs in 2022, up from $57 million in 2018, according to a new KFF analysis. Medicare began covering Ozempic for people with diabetes in 2018, with Rybelsus and Mounjaro joining in 2019 and 2022, respectively. The KFF study examined gross spending, which does not take into account any rebates paid by drug manufacturers that would lower Medicare spending. The drugs’ popularity and prices could end up raising costs for both the federal government and Medicare enrollees broadly. Medicare could choose Ozempic and Rybelsus for its drug negotiation program as early as 2025, KFF wrote, which could lower spending on the medications.
Persons: Mounjaro, ” KFF, KFF Organizations: CNN, Medicare, US Food and Drug Administration, Congressional
Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Demand for weight loss drugs is booming in the U.S. despite their limited insurance coverage and roughly $1,000 monthly price tags before discounts. The findings on how much patients are willing to spend underscore concerns about equity in access to the breakthrough drugs while insurance coverage is sparse. GLP-1s include Novo Nordisk 's blockbuster weight loss injection Wegovy and diabetes counterpart Ozempic, along with Eli Lilly' s popular weight loss treatment Zepbound and diabetes injection Mounjaro. Both Novo Nordisk and Eli Lilly have savings programs that aim to reduce out-of-pocket costs for weight loss drugs, regardless of whether a patient has commercial insurance coverage.
Persons: Eli Lilly Organizations: Novo Nordisk, ISI Locations: London, Britain, U.S
Please note, that Abbott Laboratories is not listed below as we did not own the name before the company's earnings release. Meta Platforms had one of the best earnings reports of the entire season, as sales, earnings, and cash flow trounced expectations. Despite missing earnings expectations, Coterra Energy delivered where it matters most: discretionary and free cash flow. Honeywell 's earnings results weren't great, with sales missing across the board and segment profit results coming up mixed. Given the stock's reaction, one might wonder why we don't think the earnings results from Palo Alto Networks were flat-out ugly.
Persons: we've, Eaton, Eli Lilly, Mounjaro, Bausch, Estee Lauder, Fabrizio Freda's, Linde, shouldn't, Morgan Stanley, Procter & Gamble, Stanley Black, Decker, We're, Wells Fargo, Nikesh Arora, Palo, they've, Locker, Jim Cramer's, Jim Cramer, Jim, Satya Nadella, Nadella, SeongJoon Cho Organizations: Abbott Laboratories, Wall, GE Healthcare, Meta, Microsoft, Investors, Nvidia, Wynn Resorts, Pharmaceuticals, Broadcom, Coterra Energy, Disney, Federal Deposit Insurance Corporation, Procter &, TJX, Google Services, Constellation Brands, Costco Wholesale, Costco, DuPont, Honeywell, Palo Alto Networks, Palo Alto, Management, Jim Cramer's Charitable, CNBC, Bloomberg, Getty Locations: U.S, Ford, China, Macao, Las Vegas, Boston, Wells Fargo underdelivered, Seoul
Oprah Takes on Weight Stigma in the Ozempic Era
  + stars: | 2024-03-18 | by ( Dani Blum | ) www.nytimes.com   time to read: +1 min
Oprah Winfrey, a longtime figure in the national conversation about dieting and weight bias, devoted an hourlong prime-time special on Monday to the rise of weight loss drugs. Her goal, she said, was to “start releasing the stigma and the shame and the judgment” around weight and weight loss — starting with her own, she said. “For 25 years, making fun of my weight was national sport,” Ms. Winfrey said in the show, titled “An Oprah Special: Shame, Blame and the Weight Loss Revolution.”Shame has become a focal point in that conversation as new drugs like Ozempic and Mounjaro, which are widely used for weight loss, shift how people think about treating obesity. When Ms. Winfrey disclosed in December that she was taking a medication to manage her weight, she said she was “done with the shaming” that had followed her through decades of dieting. Many patients who start taking these medications say they have felt shamed for struggling with their weight, and then shamed for taking weight loss drugs, said Dr. Michelle Hauser, the obesity medicine director of the Stanford Lifestyle and Weight Management Center, who was not involved with the special.
Persons: Oprah Winfrey, Ms, Winfrey, Michelle Hauser Organizations: Stanford, Management
CNBC's Jim Cramer backs Wall Street's upgrade of PepsiCo but warns that weight loss drug risks could have a lasting impact on the beverage and snacks giant. Shares of PepsiCo rose 4% in Monday morning trading on a bullish call from Morgan Stanley. Morgan Stanley analysts did address GLP-1s in Monday research note, saying the long-term risk is real but manageable. They added this risk "seems more than priced in" to the valuation of PepsiCo stock. Novo Nordisk is the maker of Ozempic for diabetes and Wegovy for weight loss.
Persons: CNBC's Jim Cramer, Wall, Morgan Stanley, Cramer, he's, Eli Lilly Organizations: PepsiCo, Novo Nordisk, Trust, CNBC, Club
BofA also raises red-hot server maker Super Micro Computer price target to $1,280 from $1,040. The Club stock took off in mid-February after the previous secondary. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Eli Lilly, BofA, ByteDance, Morgan Stanley's Adam Jonas, Jonas, Morgan Stanley, Tesla, Wells, Jim Cramer's, Jim Cramer, Jim Organizations: Investors, Bank of America, Electric, GE Healthcare, Club, Auto, General Motors, Ford, Citigroup, Constellation Brands, Citi, Nielsen, Corona, Modelo, Jim Cramer's Charitable, CNBC Locations: Pacifico, Cleveland
The analysts say in 2024 look for consumer packaged goods companies with volume growth, which has been our view, too. The analysts say "stay the course" and have trust that leadership will innovate. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Morgan Stanley, Eli Lilly, Oppenheimer, Jefferies, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Procter & Gamble, Nike, Guggenheim, Netflix, UBS, Apple, Troubled, Adobe, Jim Cramer's Charitable, CNBC Locations: Truist, U.S
Weight-loss drugs like Mounjaro and Ozempic are hot topics in popular culture. But only 1% of US adults currently use weight-loss drugs. Bank of America predicts that 15% of US adults will use these drugs by 2035. NEW LOOK Sign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. This story is available exclusively to Business Insider subscribers.
Persons: , Charles Barkley, Sydney Sweeney, Oprah Winfrey, Elon Musk Organizations: Bank of America, Service, Business
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Oppenheimer, BofA, Jim, Eli Lilly's, Lilly, Jim Cramer's Organizations: CNBC, Nasdaq, Dow, Wall Street, Broadcom, Bank of America, Club, FDA
Oprah Winfrey will not seek reelection to the board of WW International, known as WeightWatchers. It was a surprising time to jump on board — WeightWatchers had been shedding users, and its stock price was dwindling. AdvertisementDespite not naming the brand, there was an immediate spike in demand for GLP-1 medications — the popular new class of weight-loss drugs. That same day, WW added a weight-loss drug arm to its business, acquiring Sequence, a service that provides weight-loss drugs. AdvertisementLong-term, WW needs to find a new identityOver time, WW will benefit from being a purveyor of hard-to-access weight-loss drugs.
Persons: Oprah Winfrey, , Oprah giveth, Oprah taketh, maven, Winfrey, — WeightWatchers, Axios, Oprah, Forbes, Craig, Alex Fuhrman, Winfrey's, We're, Atkins Organizations: WW International, Service, SEC, Guardian, People Magazine, MarketWatch, Mayo Clinic, Business, Smithsonian's National Museum of, CNBC, Slate Locations: GLP, WeightWatchers
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.
Persons: Jim Cramer, Dow, Jim, Chris Danely, Cramer, Eaton, Eli Lilly, Lilly, Jim Cramer's Organizations: CNBC, Dow, Nasdaq, Semiconductor, Citi, Broadcom, Nvidia, Devices, Micron, Dell Technologies, Autodesk, Novo Nordisk, Abbott Laboratories, Novo, Viking, Jim Cramer's Charitable
Biotech company Viking Therapeutics saw stock prices double after a report on weight loss drug VK2735. The new drug could lead to even more weight loss at a faster pace than Ozempic or Mounjaro. Viking Therapeutics, a small California-based biotech company, shared the topline results from a mid-stage trial of its drug VK2735 on February 27. AdvertisementHowever, the early results of clinical trials suggest it could be on par to offer even more weight loss in less time than its competitors. How Viking Therapeutics' weight-loss drug worksVK2735 mimics two hormones that affect weight control.
Persons: , Eli Lilly, GIP, VK2735 Organizations: Biotech, Viking Therapeutics, Service, Novo Nordisk, Washington Post, Therapeutics, Viking Locations: California
COST 5Y mountain Costco's stock performance over the past five years. DHR 5Y mountain Danaher's stock performance over the past five years. ETN 5Y mountain Eaton Corp.'s stock performance over the past five years. "The megatrends are real serious, and [Eaton] is a real serious company," Jim said. TJX 5Y mountain TJX Companies' stock performance over the past five years.
Persons: Jim Cramer, Jeff Marks, Morgan Stanley, Wall, Beijing's, Jim, Eaton, Linde, Lilly's, Eli Lilly, We've, Zepbound, Mark Zuckerberg's, Mark Zuckerberg, OpenAI, Copilot, management's, Nvidia, TJ Maxx, TikTok, Gen Zers, TJX, Jim Cramer's, Satya Narayana Nadella, Lucas Jackson Organizations: GE Healthcare, Meta, Microsoft, Johnson, Natural Resources, Starbucks, Apple, Apple Music, Services, Amazon, Amazon Web Services, Prime, Costco, Danaher, Eaton Corp, Investors, GE, LIN, Novo Nordisk's Wegovy, Novo Nordisk, Management, Nvidia, TJX Companies, Marshalls, CNBC Locations: Eaton, China, Manhattan, New York City
If you want to understand how different the human and animal medicine and vaccine industries have historically been, you don't need to look much further than weight loss drugs. When Pfizer spun off its animal health business in 2013 creating Zoetis, about 65% of the company's business was livestock-related. That has flipped now, with 64% of the company's revenue coming from products for companion animals like cats and dogs. Peck credits the Pfizer spinoff for allowing Zoetis to better balance what the company wanted to do in animal health versus the human health side. A similar product was approved for cats, marking the first time that monoclonal antibody treatments, which have become increasingly popular for treating human illnesses, have been used to treat pet osteoarthritis pain.
Persons: Kristin Peck, Eli Lilly, Peck, Zoetis, We've, it's, We'll Organizations: CNBC, Novo Nordisk, Pfizer, AstraZeneca, FDA
Washington, DC CNN —The US economy is set to reap considerable benefits from Americans taking popular medications used for weight loss, including Ozempic and Wegovy, Goldman Sachs analysts wrote in a recent research report. Originally developed to treat type 2 diabetes, they proved to be highly effective at helping people shed weight in clinical trials. (Ozempic has not been approved for weight loss by regulators, though Wegovy, a similar drug, has.) Goldman Sachs argues that since poor health unambiguously weighs on the economy, improving health outcomes due to GLP-1s could lower costs and boost productivity, shoring up economic output. For some Americans who are obese but don’t have diabetes, obtaining those drugs has become difficult, if not impossible.
Persons: Goldman Sachs, Eli Lilly, Jody Dushay, Beth, Doug Langa, they’ve Organizations: DC CNN, Government, Novo Nordisk, Beth Israel Deaconess Medical, CNN Locations: Washington, United States, North America, Novo
Shares of Viking Therapeutics soared more than 80% in premarket trading Tuesday after the company's experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could grow into a $100 billion market by the end of the decade. Separately, the company said it expects to release early-stage trial data on an oral version of its weight loss drug. Viking Therapeutics' drug targets GLP-1 and another hormone called GIP. Those are the same hormones that Eli Lilly's weight loss and diabetes drugs, Zepbound and Mounjaro, target.
Persons: Brian Lian, Eli Lilly's Organizations: Viking Therapeutics, Viking, Food and Drug Administration
Jim Cramer's daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. Walmart : The Arkansas-based retail giant's 3-for-1 stock split went into effect Monday, and Jim Cramer said he'd like to see other companies consider taking similar moves. "This is something that [CEO] Doug McMillon said that [founder] Sam Walton liked because people don't like partial stock. I think that companies like Broadcom should be listening to that, and they should be splitting," Cramer said. "They gave you a really long-term view, and it was very positive," Cramer said.
Persons: Jim Cramer's, Jim Cramer, Cramer, Doug McMillon, Sam Walton, Berkshire Hathaway, Warren Buffett's, there's, Buffett, it's, Boehringer Ingelheim, Eli Lilly, Organizations: CNBC, Club, Walmart, Broadcom, Cramer's Charitable Trust, Berkshire, Zealand Pharma Locations: Arkansas, Cramer's, Arbor , Michigan, Danish
The US economy will see a surge in growth as more people start to take GLP-1 weight loss drugs. "The main reason we see economic upside from healthcare innovation is that poor health imposes significant economic costs," Goldman Sachs said. The more people that take GLP-1 weight loss drugs, the faster the US economy will grow, according to estimates from Goldman Sachs. The bank said in a note on Thursday that US GDP would grow by an extra 1% if 60 million Americans took GLP-1 drugs by 2028. There are several channels through which poor health weighs on economic activity that could diminish if health outcomes improve," Hatzius said.
Persons: Goldman Sachs, , Jan Hatzius, Hatzius, Eli Lilly, Goldman Organizations: Service, Goldman, Novo Nordisk
We discussed that for many people, the most powerful tools for medical weight management are the glucagon like peptide 1 (GLP1) agonists. As of 2024, insurance, not body weight or BMI, has become the most important vital sign for doctors who see patients for medical weight management. They really did transform a fairly barren landscape of pharmacotherapeutic options for medical weight management that lasted several decades. Weight loss is on average about 15% with Wegovy and 22% with Zepbound, with super responders losing more than 25% of their body weight. By comparison, other medications that are FDA-approved for weight loss, including Qsymia and Contrave, are combinations of much older drugs.
Persons: Jody Dushay, MMSc, Beth, I’ve, Stanley, , cravings Organizations: Medicine, Harvard Medical School, Beth Israel Deaconess Medical, CNN, Insurance, FDA, Medicare Locations: Boston, prediabetes
On the agenda today:AdvertisementBut first: Job anxiety is gripping the once-cushy Big Tech industry . ReutersDispatchA Big Tech reckoningWondering what happened to the free lunches and merch in Big Tech? The acronym, which stands for Zero Interest Rate Phenomenon, has become Silicon Valley shorthand for a changed workplace. Whereas before Big Tech companies couldn't hire quick enough, now it's laser focused on reducing layers . AdvertisementBut amid increased competition, an end to cushy perks, and the risk that they might wake up one day to find their office badge no longer works, many working in Big Tech feel … well, a little less special .
Persons: Gen, Aki Ito, she'd, Gen Xers, David Vades Joseph, Rob Dobi, doomsayers, they're, Jake Epstein, Scott Stapp, Matt Turner, Dan DeFrancesco, Jordan Parker Erb Organizations: Business, Big Tech, Reuters, Microsoft, Meta, BI Boomers, US Navy, Navy, Phoenix Locations: Big Tech, Big, Red, New York
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Eli Lilly, Morgan Stanley, it's, Wells, Jim Cramer's, Jim Organizations: CNBC, Investors, Federal, Analysts, Wells, Currency Locations: Wells Fargo
On Friday, Flynn raised his price target on Lilly shares to $950 from $805. With Lilly's stock closing Thursday at $757.78, the target suggests 25% more upside ahead. LLY 1Y mountain Eli Lilly shares over the past year. "LLY is establishing high barriers to entry in the diabesity market," Flynn said, adding that this is what contributes to its higher valuation. Phase 3 data is expected on orforglipron in 2025, which Flynn sees as a catalyst for the stock to go higher.
Persons: Eli Lilly, Morgan Stanley, Terence Flynn, Flynn, Lilly, Mounjaro, — CNBC's Michael Bloom Organizations: Novo Nordisk Locations: diabesity
How to access the new weight loss drugs
  + stars: | 2024-02-15 | by ( Andrea Kane | ) edition.cnn.com   time to read: +7 min
(CNN) — By now, it is pretty clear that the new weight loss and diabetes medications have achieved blockbuster status. Unlike previous weight loss medications, they are pretty effective at helping people lose weight and keep it off — between around 15% to 20% of body weight — with relatively few side effects (although some people can’t tolerate them, and a fraction of patients experience more severe side effects). Zepbound, the newly approved weight loss drug from Eli Lilly, may be easier to find. “Otherwise, some physicians are prescribing older, generic weight loss medications that can be helpful for some patients.”These drugs are not right for everyoneFor many people, the cultural pressure to look a certain way is high. And join us next week on the Chasing Life podcast when we talk to WeightWatchers CEO Sima Sistani about whether these new weight loss drugs really signal the end of diet culture.
Persons: Sanjay Gupta ”, Eli Lilly, Goldman Sachs, Meg Tirrell John Nowak “, Meg Tirrell, Sanjay Gupta, ” Tirrell, , ” Eli Lilly, Tirrell, , Sima Sistani Organizations: CNN, , Trilliant Health, Novo Nordisk, US Food and Drug Administration, , Nordisk,
Total: 25